Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABO-101 in primary hyperoxaluria type 1
NL-OMON59636Phase 2Not yet recruiting
- Sponsor
- Arbor Biotechnologies
- Start
- Aug 2025
- Modality
- Gene Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of ABO-101 in Primary Hyperoxaluria Type 1 (PH1), sponsored by Arbor Biotechnologies. Planned start Aug 2025; status: not yet recruiting.
02
Drugs
ABO-101
03
Conditions
Primary Hyperoxaluria Type 1 (PH1)
Beyond the preview
Go deeper on NL-OMON59636.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59636.